The global pediatric neuroblastoma treatment market is driven by the increasing incidence of neuroblastoma in children, which remains one of the most common cancers affecting children under the age of 5. Neuroblastoma accounts for approximately 6-10% of all childhood cancers, with around 650 new cases diagnosed annually in the U.S. alone. The disease is predominantly diagnosed in children younger than 5, and while it can arise in various parts of the body, it most often starts in the adrenal glands. The survival rate for localized neuroblastoma is high, but for advanced or metastatic cases, the prognosis remains challenging, with survival rates dropping significantly. Advances in treatment options, including chemotherapy, immunotherapy, and targeted therapies, are continuously improving outcomes, although the need for more effective and less toxic treatments remains critical. Additionally, the increasing prevalence of relapsed and refractory neuroblastoma highlights the demand for innovative therapies that can offer better long-term survival and quality of life for pediatric patients. Ongoing clinical trials and breakthroughs in precision medicine are expected to play a crucial role in the future treatment environment.
